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Background: The pneumococcal pilus is associated with increased inflammation.
Results: A 49-amino acid region of the pilus protein RrgA activates TLR2 and is associated with increased inflammation and
virulence.
Conclusion: The pneumococcal pilus is a TLR2 agonist; RrgA is a key component.
Significance: A better understanding of the pilus in bacterial pathogenesis is crucial for the development of novel strategies
against this pathogen.
The pneumococcal type 1 pilus is an inflammatory and adher-
ence-promoting structure associated with increased virulence
inmousemodels.We show that RrgA, an ancillary pilus subunit
devoid of a lipidationmotif, particularly when presented as part
of an oligomer, is a TLR2 agonist. The surface-exposed domain
III, and in particular a 49-amino acid sequence (P3), of the pro-
tein is responsible for the TLR2 activity of RrgA. A pneumococ-
cal mutant carrying RrgA with a deletion of the P3 region was
significantly reduced in its ability to activate TLR2 and induce
TNF- responses after mouse intraperitoneal infection,
whereas no such difference could be noted when TLR2/mice
were challenged, further implicating this region in recognition
by TLR2. Thus, we conclude that the type 1 pneumococcal pilus
can activate cells via TLR2, and the ancillary pilus subunit RrgA
is a key component of this activation.
Streptococcus pneumoniae (pneumococcus) accounts for
over 860,000 childhood deaths annually (1). The bacterium is a
frequent colonizer of the nasopharynx in children; most are
colonized by the pneumococcus at some point during the
first 2 years of life. Currently available pneumococcal vac-
cines generate potent systemic immunity via the generation of
opsonophagocytic antibodies to the capsular polysaccharide (2,
3). These vaccines, however, have limitations, including selec-
tive coverage of capsular types included in the vaccines, only
partial protection against mucosal disease, the phenomenon of
serotype replacement, and high cost (4–6). For these reasons,
alternative vaccine strategies have been sought, including the
development of multivalent protein-based vaccines or killed
whole cell vaccines (7–12).
Many surface proteins have been investigated as potential
vaccine candidates. The structural proteins of the pneumococ-
cal pilus type 1 are among the most recent ones to be investi-
gated (13–16). The type 1 pilus was shown to act as an adhesin
(17, 18), enhance colonization in amousemodel (19), and facil-
itate the formation of microcolonies and biofilms (20). Piliated
pneumococcal strains induce significantly more TNF- in a
mouse model of intraperitoneal sepsis than pilus-negative iso-
genic controls (19).
At the same time, the role of the pneumococcal type 1 pilus in
pneumococcal pathogenesis in humans remains controversial.
We have previously demonstrated that the frequency of pilus
genes was similar in strains isolated from the nasopharynx and
blood cultures from infected children, putting in question the
role of the pilus as a virulence factor (21). After the introduction
of the pneumococcal conjugate vaccine in 2000 in the United
States, the frequency of strains carrying the pilus genes declined
dramatically, as a result of the association between the type 1
pilus and the capsular serotypes covered by the vaccine (21).
However, several years later, replacement strains not covered
by the vaccine becamemuchmore common, and the frequency
of strains carrying pilus type 1 genes returned to pre-2000 lev-
els, suggesting instead that the presence of these genes may
confer an advantage to the organism (22). It is also striking that
the prevalence of the pilus across different geographic areas and
various pneumococcal clones is similar (23, 24). Complicating
the picture further, our group and others recently showed that
pilus expression is bistable among a clonal population (25, 26),
such that only roughly 30% of cells derived from one clone
express the pilus at any one time. This regulation appears to be
negatively regulated by RrgA (25) and positively regulated by
the RlrA-positive feedback loop (27).
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This intricate regulatory system suggests a complex combi-
nation of fitness benefits and costs of expression of the pilus to
the bacterium. To elucidate this further, a better understanding
of the interaction between the pilus and the host is warranted.
In the studies described below,we examined the pro-inflamma-
tory and adherent properties of the type 1 pilus. In particular,
we wished to evaluate whether the pilus engages the innate
immune receptor TLR2 and to identify components of the pilus
that may be responsible for the enhanced inflammation and
binding observed with piliated strains. Here, we show that the
structural ancillary pilus protein RrgA is a TLR2 agonist, most
potently so when presented in an oligomerized form. We fur-
ther demonstrate that a 49-amino acid region (P3) of the
domain III (DomIII)3 of RrgA is necessary and sufficient for this
activation. A pneumococcal mutant, in which P3 is deleted, is
highly attenuated with respect to TLR2 activation despite no
demonstrable defect in binding; similarly, this mutant is defec-
tive in the induction ofTNF- inmice following intraperitoneal
injection, whereas no differences between the wild type strain
and the mutant was apparent when TLR2/ mice were
infected.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Reagents—Bacterial strains and plas-
mids are listed inTable 1. Primers used in this study are listed in
Table 2. Pneumococci were grown in Todd Hewitt broth sup-
3 The abbreviations used are: DomIII, domain III; Ply, pneumolysin.
TABLE 1
Bacterial strains and plasmids used in this study
Description Source
Strain
T4 Spontaneous SmR derivative of Tigr4 On line
T4(pilus) rlrA-srtD::cm SmR, CmR 25
T4rrgA rrgA::Janus KanR 25
T4ABC rrgA-rrgC:: SmR This study
T4(rrgA-II) rrgA::rrgA-II This study
T4* Equivalent to T4 but transformed twice This study
T4p3 rrgAP3 This study
Plasmids
pAC1000 Derivative of pEV3 51
pQE30-rrgA Wild type rrgA 25
pQE-30-rrgB Wild type rrgB 25
pQE-30-rrgC Wild type rrgC This study
pET15b-DomIII Domain III of rrgA This study
pET15b-DomIII-Ply Domain III of rrgA fused with ply This study
pET15b-DomIII-Pdt Domain III of rrgA fused with pdt This study
pET15b-P1-Ply Part 1 of Domain III of rrgA This study
pET15b-P2-Ply Part 2 of Domain III of rrgA This study
pET15b-P3-Ply Part 3 of Domain III of rrgA This study
TABLE 2
Primers used in this study
Oligomerized RrgA Activates TLR2
2666 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 4•JANUARY 25, 2013
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on M
arch 6, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
plemented with 0.5% yeast extract (THY) or on tryptic-soy agar
with 5% sheep blood (TSA) plates. Antibiotics (300g/ml kana-
mycin and 600 g/ml streptomycin) were added as needed. All
pneumococcal mutants were constructed from a spontaneous
streptomycin-resistant (SmR) strain (T4) derived from the sero-
type 4 clinical isolate TIGR4. Our T4* strain of reference is a
strain in which the Janus cassette replacing the rrgA gene has
been replaced de novo by the rrgA gene, to control for any
effects of transformation. In particular, this strain was con-
firmed by flow cytometry to express the pilus in a bistable way,
in a similar pattern as the original T4 strain (data not shown)
(25). Killed pneumococcal strains were prepared by growth to
A600  0.5 and then heat-inactivated at 58 °C for 1 h. Esche-
richia coli strains were grown in LB medium supplemented
with 100 g/ml ampicillin as needed. Antibodies to RrgA and
RrgB were obtained as described previously following purifica-
tion of recombinant His6-tagged RrgA and RrgB and immuni-
zation of guinea pigs and rabbits, respectively (at Cocalico Bio-
logicals, Inc.) (25).
Human TNF- was obtained from Human PeproTech
(Rocky Hill, NJ). Ultrapure LPS and CLI-095, a cyclohexene
derivative that specifically suppressesTLR4 signaling (28), were
obtained from InvivoGen (San Diego).
Cloning Strategies—DNA cloning strategies were based on
overlapping PCR and other previously described techniques
(25). Pneumococcal mutants were generated using the bicis-
tronic Janus cassette (29) and then sequenced. The strain
T4(Pilus) was described previously (25). A strain deleted for
the rrgA or rrgB using Janus was thus constructed. The cassette
was then replaced by overlapping PCR strategy to create
mutants of the RrgA protein. In particular, to evaluate the abil-
ity of RrgA of different clades, we replaced the endogenous rrgA
gene in TIGR4 by the rrgA-II (clade II) gene using genomic
DNA from a clinical pneumococcal isolate that expresses a
clade II pilus type 1 (a gift of J. Finkelstein, Boston Children’s
Hospital). We also created a mutant with a deletion of 49
amino acids of the DomIII (P3) of the RrgA protein. The
DNA sequence of this mutant was confirmed. A T4ABC
strain was generated by first replacing rrgA, rrgB, and rrgC
genes by the Janus cassette, and then removing the Janus
cassette by overlapping PCR. All constructs were confirmed
by PCR and Western blotting analysis where applicable and
sequence.
Cell Lines—Human embryonic kidney (HEK) cell lines stably
transfected with TLR2 or TLR4 have been described previ-
ously (30). These cells were maintained in DMEM with 10%
FBS, 10 g/ml ciprofloxacin, and 1 mg/ml G418. Murine
macrophage cell lines derived from C57BL/6 mice that do or
do not express TLR2 have also been described previously
(31) and were maintained in DMEM with 10% FBS and 10
g/ml ciprofloxacin.
Protein Cloning, Purification, and Expression—His6-tagged
RrgA and RrgB were described previously (25). His6-tagged
RrgC was cloned into pQE30, whereas DomIII(Gly212–Ser592),
DomIII-Ply, DomIII-PdT, P1(Phe403–Glu437)-Ply, P2(Gly423–
Glu458)-Ply and P3(Lys459–Ser507)-Ply were cloned into
pET15b. Protein expression and purification were done as
described previously (25). To separate the proteins by size, the
proteins obtained by elution from the nickel-nitrilotriacetic
acid column were then passed over a gel filtration column
(Superdex 200 column) in a buffer containing 20 mM Tris, pH
8.0, 150 mM NaCl as the running solution. The fractions con-
taining target proteins of different sizes (reflecting different
degrees of aggregation) were collected separately, tested by
SDS-PAGE, and tested for TLR2 activity on HEK-TLR2 cells as
described below. The protein concentrations were determined
using a BCA protein assay kit from Bio-Rad.
Measurement of Inflammatory Responses—Enzyme-linked
immunosorbent assays (ELISAs) for the determination of
CXCL8/interleukin-8 (IL-8) were performed on supernatants
from stimulated HEK-TLR2 or HEK-TLR4 cells. Twenty four-
well ELISA plates were coated overnight with 6  105 HEK-
TLR2 or HEK-TLR4 cells. Defined concentrations of either
heat-killed bacteria or His tag-purified proteins were added to
the wells for 16 h. Supernatants were then collected and ana-
lyzed for production of the human IL-8 using the DuoSet
ELISA kit following the manufacturer’s instructions (R&D Sys-
tems, Minneapolis, MN).
Similar experiments were performed using murine macro-
phage cell lines. In these experiments, 24-well ELISA plates
were seeded with cells pretreated with CLI-095, an inhibitor of
TLR4 responses, before the addition of defined concentrations
of purified proteins for 16 h. Cell supernatants were harvested
and assayed for murine TNF- using the DuoSet ELISA kit
(R&D Systems).
Bacterial Adherence Assays—Bacterial adherence assays
were performed as described previously (40) with slight modi-
fications. A549 human lung cells were obtained from theAmer-
ican Type Culture Collection (Manassas, VA) and grown
according to recommended guidelines. Cells were seeded onto
24-well tissue culture plates to reach near-confluence at the
time of the experiment. Bacterial cells were grown to mid-log
exponential phase (A600  0.5) and then washed in PBS, and
aliquots were saved in 20% glycerol at 80 °C. Individual ali-
quots were used for each experiment. About 107 cfu/ml were
added toA549 cells, resulting in amultiplicity of infection of 10.
After 3 h of incubation at 37 °C and 5% CO2, cells were rinsed
three times with PBS to remove nonadherent bacteria. A549
cells were then detached from the plate with 200 l of 0.25%
trypsin, 1 mM EDTA and solubilized with 800 l of ice-cold
0.025% Triton X-100. Dilutions were plated on TSA plates.
Percentage of binding was calculated by dividing the recov-
ered number of bacteria by the input number after setting
the T4 percentage at 100%. Each experiment was performed
in triplicate, and the experiment was repeated three times on
separate days. Representative results are shown in all cases.
Protein Adherence Assays—Immulon 2 HB 96-microwell
plates (Thermo Scientific, Waltham, MA) were coated over-
night at room temperature with 5g/ml selected proteins. The
next day, wells were washed and blocked with a solution of 1%
bovine serum albumin (BSA) in PBS for 1 h. Wells were rinsed
three times with PBS. HEK293, HEK-TLR2, or HEK-TLR4
cells, previously detached from their flask and resuspended in
adequate cellmedia at a concentration of 5 105 cells/ml for 30
min at 37 °C, were then added onto the blocked plate for 1 h at
37 °C. Plates were then shaken gently to lift nonadherent cells
Oligomerized RrgA Activates TLR2
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and fixed for 15 min in 70% ethanol. After three PBS washes,
cells were stained in crystal violet for 2 min and then rinsed
thoroughly with water. Finally, the stain was recovered by cell
solubilization in 10% acetic acid solution, and A590 was read.
Each conditionwas performed in triplicate, and the experiment
was repeated at least three times. Representative results are
shown.
Flow Cytometry—Flow cytometry analyses to evaluate the
percentage of cells that express the pilus were performed as
described previously (25). Briefly, analysis was performed on a
Beckman Coulter MoFlo Legacy flow cytometer. Post-acquisi-
tion analysis was performed using Beckman Coulter Summit
4.3 software and Treestar FlowJo 8.7.3. Heat-killed bacteria
were blocked for 1 h in Buffer 0 (PBS 1with 1% BSA), treated
for 1 hwith primary antibody in Buffer 1 (PBS 1, 0.05%Tween
20, 1%BSA), washed oncewith Buffer 1, and then treated for 1 h
with secondary antibody in Buffer 1. Bacteria were washed
three times in Buffer 1 and analyzed by flow cytometry using
MoFlo. The experimentswere performed at room temperature.
Alexa Fluor 488 or 660 secondary antibodies from Invitrogen
were used at a dilution of 1:50.
Mouse Sepsis Model—Four- to 6-week-old C57BL/6J female
mice or TLR2/ isogenic controls were intraperitoneally
injectedwith 200l of THYcontaining 108 cfu/ml of the appro-
priate pneumococcal strain; per experiment, 15 mice were
injected with each pneumococcal strain. At 6 h post-infection,
blood was taken on each mouse to measure the density of bac-
teremia and TNF- concentration in serum samples. The den-
sity of bacteremiawas evaluated by serial dilution of blood sam-
ples in PBS and plating on blood agar plates. TNF-
concentrations were measured using the mouse TNF-/
TNFSF1A DuoSet ELISA kit following the manufacturer’s
conditions (R&D Systems). For each mouse, we report the
TNF- production at 6 h post-infection.
Statistical Analysis—TNF- concentration and density of
bacteremia in mice were compared by the Mann-Whitney U
test, using PRISM (version 4.0a, GraphPad Software, Inc).
RESULTS
Pneumococcal Pilus Enhances TLR2-mediated Inflammatory
Responses to Whole Killed Pneumococci—Previous work
showed that deletion of the rlrA pathogenicity islet encoding
the type 1 pilus of T4 leads to attenuated TNF- and IL-6
responses in mice after intraperitoneal challenge (10). We
began our investigations by evaluating whether the presence of
the pilus on live or dead pneumococci had a different effect on
cellular inflammatory responses. To this end, live or heat-killed
T4 strain or aT4 strainwith a deletion of thewhole islet respon-
sible for pilus expression (T4(Pilus)) were used to stimulate
murinemacrophage cell lines or human embryonic kidney cells
(HEK293, expressing TLR2 or TLR4).
Pneumococci induce a range of inflammatory responses
from cells due, at least in part, to TLR2, TLR4, and TLR9
responses to lipoteichoic acid (32), pneumolysin (33), and
unmethylated CpG motifs in DNA (34), respectively, so that a
specific effect of the pilus proteins may be difficult to observe.
Therefore, we hypothesized that a differential effect of the pilus
may best be initially observed in cells with a more limited rep-
ertoire of responses. S. pneumoniae is known to activate both
TLR2 and TLR4 (32, 33, 35); thus, we wished to evaluate if
either of these receptorsmay confer inflammatory responses to
the pilus. Transfected HEK cells expressing either TLR2 or
TLR4 were stimulated with heat-killed T4 strain or the
T4(Pilus) strain. The concentration of IL-8 expression in cell
supernatants, a marker of TLR2 or TLR4 activation in HEK-
TLR2 or HEK-TLR4 cells, respectively, was determined after
16 h of incubation by ELISA (Fig. 1A). As expected, stimulation
of HEK-TLR2 cells with killed wild type pneumococci elicited
IL-8 expression in a dose-dependent manner (Fig. 1A); in com-
parison, IL-8 expression was significantly attenuated when
HEK-TLR2 cells were stimulated with the T4(Pilus), suggest-
ing that the pneumococcal pilus augments the TLR2-depen-
dent responses to killed pneumococci. Identical results were
obtained with a strain carrying a deletion of the rrgA, rrgB, and
rrgC genes or a strain with a deletion of the pilus regulator rlrA
(data not shown) suggesting that this decrease in TLR2 activa-
tion is likely due to the absence of these structural proteins
rather than the absence of the RlrA transcription factor.
RrgA Protein Activates TLR2—The findings above could be
consistent with two nonmutually exclusive hypotheses as fol-
lows: (a) one or more proteins that form the pilus (RrgA, RrgB,
and RrgC proteins) may be TLR2 agonists, and/or (b) because
the pilus has been shown to enhance binding of pneumococci to
epithelial cells via the RrgA protein, the increased inflamma-
tory response may be a direct result of increased binding of
piliated bacteria to epithelial cells. To evaluate these possibili-
ties, we purified the three structural proteins of the pilus. Con-
sistent with previous findings (17), we confirmed that the
recombinant RrgA immobilized to a surface functions as an
adhesin, to a similar extent on HEK293, HEK-TLR2, or HEK-
TLR4 cells (Fig. 1B); in contrast, wewere unable to demonstrate
suchproperty for theRrgBorRrgCprotein. To testwhether any
of these proteins activates TLR2, we stimulated HEK-TLR2
(Fig. 1C) and control HEK-TLR4 cells with a range of concen-
trations of proteins (Fig. 1D). No IL-8 expression was detected
from the HEK-TLR4 cells with any of the single proteins con-
firming the data obtained when the cells were stimulated with
whole bacteria (Fig. 1D) (these cells do not express MD-2 and
are thus largely unresponsive to any possible contaminating
LPS). In contrast, activation of HEK-TLR2 cells was readily
observed with RrgA, with RrgB and RrgC being far less potent
(Fig. 1C). Thus, we decided to focus the remainder of our stud-
ies on RrgA.
Because most previously described TLR2 ligands or agonists
are either lipids or lipid-modified polysaccharides or proteins,
we asked if the TLR2 activity of RrgA is due to intrinsic lipida-
tion of the molecule. Bioinformatic analysis on the sequence of
RrgA did not identify any obvious lipidation motif or site. Fur-
thermore, a MALDI-TOF mass spectrometry analysis was per-
formed on the purified full-length RrgA protein (PrimmBiotech,
Cambridge, MA), and no lipidated peptide fragment could be
identified. These results strongly suggest that the TLR2 activity
of RrgA is mediated by the protein itself rather than by the
presence of a lipid moiety in the molecule.
To obtain further confirmation that RrgA is a TLR2 activa-
tor, we repeated similar experiments in HEK-TLR2 cells using
Oligomerized RrgA Activates TLR2
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killed preparations of pneumococci, including a strain that
lacks either the three structural proteins or RrgA. As we have
shown previously (25), the T4rrgA strain makes a polymer-
ized pilus (as detected by Western blotting analysis using
RrgB antibodies). As shown in Fig. 1E, in the absence of
RrgA, the killed pneumococcal preparation is far less stimu-
latory of HEK-TLR2 cells, to the same extent as the T4ABC
strain. These data therefore imply that, within the context of
the intact pneumococcal cell, RrgA is the main activator of
TLR2.
Recognizing that HEK-TLR2 cells represent a somewhat
artificial construct, we next evaluated the TLR2 stimulatory
properties of RrgA and RrgB in murine macrophages without
orwith a deletion ofTLR2. Because these proteinswere purified
in E. coli, and to remove the effect of any potential LPS contam-
ination, all the stimuli in these experiments were pretreated
with CLI-095, a specific inhibitor of TLR4 signaling (28). As
shown in Fig. 1F, RrgA and, to a lesser extent, RrgB stimulated
TNF- release from the wild type macrophages, although this
response was completely abrogated in TLR2/macrophages,
implying that this response, now observed in murine macro-
phages, is indeed TLR2-dependent.
Aggregation Enhances TLR2 Activity of RrgA—By gel filtra-
tion chromatography, the purified RrgA protein was separated
by size into three major fractions, representing different aggre-
gation states. By the apparentmolecularweight calculated from
the chromatography profile, we called these three fractions
monomer (M1), small aggregates (SA1), and large aggregates
(LA1), respectively (Fig. 2, inset). The three fractions, along
with the nonfractionated RrgA protein, were used to stimulate
HEK-TLR2 cells at equal concentrations. Strikingly, whereas
the monomeric RrgA (M1) fraction led to very little TLR2 acti-
vation, stimulation ofHEK-TLR2 cells with the same amount of
protein in the SA1 or LA1 fractions gave much more potent
TLR2 activation, by inducing a 3.6-fold (SA1) and 21-fold (LA1)
higher concentration of released IL-8 than did the monomer
RrgA (Fig. 2). This result suggests that aggregation of RrgA
significantly enhances TLR2 activation.
FIGURE 1. Type 1 pneumococcal pilus enhances TLR2-dependent inflammatory responses in human epithelial cells. A, transfected HEK cells expressing
TLR2or TLR4were stimulatedwith increasing concentrations of heat-killed T4or T4(Pilus) pneumococcal strains. IL-8 expressionwasquantifiedby ELISA after
16 h of incubation. Although heat-killed pneumococci did not stimulate IL-8 responses in HEK-TLR4 cells, a dose-dependent IL-8 elicitation in HEK-TLR2 cells
was observed andwas significantlymorepronouncedwhenpiliatedbacteriawere used.B, 96-well plateswere coatedwith 5g/ml of various proteins (bovine
serum albumin (BSA), fibronectin, RrgA, RrgB, and RrgC orwithout protein coating) overnight at room temperature. HEK293, HEK-TLR2, or HEK-TLR4 cells were
added to the wells at a concentration of 5 105 cells/ml for 1 h at 37 °C. Wells were washed and bound cells were stained with crystal violet; A590 measured.
Although no binding could be demonstrated with RrgB or RrgC, RrgA demonstrated strong binding to cells. C and D, increasing concentrations of purified
proteins RrgA, RrgB, and RrgC were used as stimuli for HEK-TLR2 (C) and HEK-TLR4 (D) cells; supernatants were assayed for IL-8 expression after 16 h of
incubation. IL-8 expression in HEK-TLR4 cells was negligible, whereas the pilus proteins induced dose-dependent expression of IL-8 fromHEK-TLR2 cells. On a
molar basis, the RrgAproteinwas themost potent activator of TLR2. The TLR2 agonist Pam3Cysk (1g/ml)was used as a control inHEK-TLR2 cells; for HEK-TLR4
cells, which do not express MD-2, recombinant TNF- (50 ng/ml) was used. E, IL-8 responses of HEK-TLR2 cells following stimulation with heat-killed pneumo-
coccal preparations (wild type T4* and strains T4ABC and T4rrgA) at the listed concentrations (per ml) for 18 h. Cell supernatants were then collected and
assayed for IL-8 concentration. There was a clear dose-dependent IL-8 response, greater in the wild type bacterial preparation when compared with the two
other strains, which both stimulated the cells to a similar degree, implying a role of RrgA in TLR2-dependent responses in the context of whole bacteria. F,
TLR2-dependent responses to pilus proteins evaluated in murine macrophages. Purified proteins RrgA, RrgB, and RrgC were used to stimulate murine
macrophages derived from C57BL/6 and isogenic TLR2/ knock-out mice. To eliminate confounding by possibly LPS contamination, the stimuli were all
pretreated with the specific TLR4 inhibitor CLI-095, as described in the text. Both RrgA and RrgB elicited dose- and TLR2-dependent responses from the cells.
Controls includedPam3Cysk (1g/ml) and LPS (with andwithoutCLI-095pretreatment, 100ng/ml). All these experimentswereperformedat least three times,
with triplicate wells per experiment. Representative results are shown, and error bars represent standard deviations.
Oligomerized RrgA Activates TLR2
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Domain III of the RrgA Protein Activates TLR2—Crystal
structure analysis of the RrgA protein reveals four major
domains (Fig. 4A) (36), where domain IV is thought to be
responsible for the interaction with RrgB. and domain III is
extended to the outside of the pilus. We hypothesized that
domain III may be more likely to interact with cell surface
receptors, such as TLR2. To evaluate this possibility, we
expressed and purified domain III of RrgA. By gel filtration
chromatography, the recombinant domain III was found to
form a smaller rather than a larger aggregate as the full-length
RrgA (Fig. 3A, inset). When used to stimulate HEK-TLR2 cells,
the purified domain III did not induce a significant IL-8
response (Fig. 3A). To further oligomerize domain III, a fusion
protein was made by genetically fusing domain III with pneu-
molysin (Ply), a toxin known to be able to lyse cells by forming
a large pore-like oligomer on the cell membrane. A similar
fusion protein was constructed in which domain III was fused
to PdT, the pneumolysinmutant (W433F, D385N, and C428G)
that is unable to oligomerize (37). As expected (38), the domain
III-pneumolysin fusion protein (DomIII-Ply) was present in
three different forms in solution as follows: a monomer (M2), a
small oligomer (SO2), or a large oligomer (LO2) (Fig. 3B). In
contrast, the domain III-PdT fusion protein (DomIII-PdT) was
present only as a monomer in solution (Fig. 3B). When these
fusion proteins were used to stimulate HEK-TLR2 cells,
DomIII-Ply, but not DomIII-PdT, induced strong inflamma-
tory responses comparable on a molar basis with the one
observed with the RrgA protein (Fig. 3C). Furthermore, when
stimulating cells with DomIII-Ply fractions of different sizes,
the large oligomer (LO2) showed significantly higher TLR2
activity than the small oligomer (SO2) or the monomer (M2)
(Fig. 3D), consistent with our prior observations with RrgA.
A 49-Amino Acid Region (P3) of the DomIII of the RrgA Pro-
tein Is Necessary and Sufficient to Activate TLR2—We trun-
cated RrgA further to more precisely identify a region that may
be responsible for TLR2 activation. Domain III of the RrgA
protein can be divided into two parts as follows: a well struc-
tured core domain (Fig. 4A, gray structure), which is physically
connected to domain II, and a peripheral fragment that is very
much exposed at the distal end of RrgA andmay be easily acces-
sible with less steric hindrance (Fig. 4A). Thus, we tested if this
peripheral fragment would activate TLR2 responses. Three
peptides of 35 (P1, Fig. 4A, in blue), 36 (P2, Fig. 4A, in green),
and 49 amino acids (P3, Fig. 4A, in red) in length were designed
to cover the sequence from residue 403 to 507. The three pep-
tides were fused to Ply and tested for TLR2 activation (Fig. 4B).
When tested onHEK-TLR2 cells, only the P3-Ply fusion protein
was able to activate TLR2 and at roughly the same potency as
the RrgA protein, suggesting that this 49-amino acid sequence,
when presented as a oligomer, is sufficient to activate TLR2
(Fig. 4B).
The type 1 pneumococcal pilus can be divided into clades I,
II, and III (to which the TIGR4 type 1 pilus is most closely
related) (39). We evaluated the sequence similarities between
the three clades, which revealed that although the P3 region of
clades I and III were highly conserved, there were greater dif-
ferences between clade II and our RrgA protein (Fig. 4C). There
is60% homology at the amino acid level in the P3 region, with
the absence of five residues in RrgA II (corresponding to the last
-sheet motif in RrgA) just before a very conserved C-terminal
loop region (Trp496–Ser507). To evaluate whether the clade II
RrgA protein can activate TLR2, we replaced the rrgA gene
found in our TIGR4 strain with the clade II gene, as described
under “Experimental Procedures.” This new strain (designated
T4(rrgA II)) was compared with the T4 strain for pilus expres-
sion, formation, and its ability to stimulate HEK-TLR2 cells. As
shown, there were no appreciable differences in the amount of
pilusmade by the two strains nor the appearance of the pilus by
Western blotting (Fig. 4D). Furthermore, there were no differ-
ences in the ability of either killed bacterial preparations to
activate TLR2, and both were significantly more active when
compared with a strain with a deletion of rrgABC (Fig. 4E).
Thus, we conclude that RrgA from clade II can similarly acti-
vate TLR2, perhaps due to the homology with clade III.
We and others showed that individual clones of piliated
pneumococci can have very different pilus expression patterns,
such that the comparison of a wild type strain with one carrying
a modification in the rrgA gene should include an examination
of the pattern of pilus expression (25, 26). To control for these
issues, we confirmed byWestern blot and flow cytometry stud-
ies that a pneumococcal mutant carrying the rrgA gene with a
deletion of the corresponding sequence of the P3 (T4P3)
expresses the pilus in the same pattern as the wild type strain
(Fig. 4F). HEK-TLR2 cells were then stimulatedwith heat-killed
preparations of the three pneumococcal strain as follows: T4*,
T4(pilus), and T4P3. The T4P3 mutant stimulated HEK-
TLR2 cells to the same extent as the T4(pilus) strain (Fig. 4G),
thereby confirming the P3 region as necessary for RrgA-in-
duced TLR2 activation.
FIGURE 2. TLR2 preferentially recognizes large aggregates of the RrgA
protein. Inset, RrgA protein was further purified on a Sepharose column
(inset). Different sizes of the protein were observed, reflecting a monomeric
form (M1), a small aggregate (SA1), and large aggregate (LA1). Stimulation of
HEK-TLR2 cells with equimolar amounts of RrgA proteins of different size is
shown in the main figure. The larger aggregates are significantly more stim-
ulatory of TLR2 than the smaller aggregates. Error bars indicate standarddevi-
ations.mAU, milli-absorbance units.
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These data thus support the hypothesis that the enhanced
inflammatory response to piliated pneumococci is the result of
TLR2 activation by pneumococcal pilus proteins, most notably
RrgA; indeed, when the P3 domain is removed, TLR2 responses
were significantly reduced. The possibility remained, however,
that this reduction in TLR2 activation might also be due to
decreased binding of bacteria to cells rather than the elimina-
tion of the putative amino acid sequence responsible for TLR2
activation. As shown in Fig. 4H, however, the T4P3 mutant
pneumococcal strain has similar binding capacity as the T4*
strain in the adhesion assay. Thus, we conclude that the P3
region of DomIII of the RrgA protein is both necessary and
sufficient for TLR2 activation and that this property is not due
to altered binding.
P3 Region of Domain III of the RrgA Protein Contributes, in a
TLR2-dependent Fashion, to theDensity of Bacteremia and Pro-
inflammatory Response to Live Pneumococci in an Intraperito-
neal Infection Model—The virulence and inflammatory
response to T4* and T4P3 strains were compared in a mouse
model of intraperitoneal infection. Mice (n  15 per group)
were infectedwith 108 cfu of eitherT4* or theT4P3mutant by
intraperitoneal injection. At 6 h post-infection, mice were bled,
and levels of bacteremia and TNF- in the serum were deter-
mined. Both bacteremia and TNF- levels were significantly
higher in the mice that received T4* versus the T4P3 strains
(comparison of density of bacteremia and TNF- concentra-
tions, p 0.03 and p 0.004, respectively byMann-WhitneyU
analysis). The density of bacteremia andTNF- concentrations
were highly correlated (Spearman   0.59, p  0.0006). To
confirm that these differences are in fact dependent on TLR2, a
similar experiment was performed in C57BL/6 TLR2/ mice
(n  5 per group). The density of bacteremia in WT versus
TLR2/ mice was not statistically different (Fig. 5D) nor was
the concentration of TNF- from serum obtained 6 h post-
infection (Fig. 5E), with an excellent correlation between bac-
teremia and TNF- concentration (Fig. 5F). We conclude that
the P3 domain of the RrgA protein is a critical and TLR2-de-
pendent determinant of the density of bacteremia and pro-in-
flammatory response to invasive disease due to piliated
pneumococci.
DISCUSSION
Recognition of bacterial components by the innate immune
response is an effective method to protect the host against var-
ious pathogens (40). In particular, the interaction of bacterial
components with Toll-like receptors has been associated with
protection against viral and bacterial diseases (33, 41–46).
Since the first description of Toll-like receptors in humans,
there have been numerous reports of various agonists for each
receptor. TLR2 is particularly interesting in this respect, as it
appears to recognize the broadest range of bacterial com-
pounds of all the humanToll-like receptors studied to date. The
FIGURE 3. Oligomerized DomIII of the RrgA protein activates TLR2. A, monomeric form of DomIII does not activate TLR2. DomIII of the RrgA protein was
expressed in E. coli and separated on a Sepharose column. DomIII is mainly found asmonomer (M) or small aggregate (SA). Stimulation of HEK-TLR2 cells with
DomIII does not result in IL-8 production. B, Ply, PdT (a nonhemolytic mutant of pneumolysin), DomIII-Ply, and DomIII-PdT were separated by size on a
Sepharose column. Ply or a fusionofDomIIIwithPly forms largeoligomers,whereas PdTor theDomIII-PdT fusiononly formsmonomers.mAU,milli-absorbance
units.C,oligomerizedDomIII-Ply activates TLR2. Supernatants fromHEK-TLR2 cells stimulatedwithRrgA,DomIII-Ply, DomIII-PdT, andPlyproteinswere assayed
for IL-8 production. The DomIII-Ply fusion protein is as potent as the RrgA protein on amolar basis with respect to TLR2 stimulation.D, larger oligomers of the
DomIII-Ply fusionprotein aremore potent activators of TLR2. The fusionproteinwas separatedbypassage over a Sepharose column, revealing different stages
of protein oligomerization (labeledM2, SO2, and LO2, for the monomeric, small oligomers, and large oligomers, respectively) of the fusion protein. The large
oligomer of DomIII-Ply is the most potent activator of TLR2 as measured by IL-8 production in HEK-TLR2 cells. Error bars indicate standard deviations.
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broad range of activators of this receptor is exemplified by the
growing list of identified molecules that interact with TLR2,
which now includes lipopolysaccharides of certain bacteria,
lipoproteins, glycoproteins, zymosan, peptidoglycan, and lipo-
teichoic acids (reviewed in Ref. 47). Here, we add to this list of
bacterial TLR2 agonists by demonstrating that the pneumococ-
FIGURE 4. P3 region of DomIII is necessary and sufficient for pilus-dependent TLR2 activation. A, schematic arrangement and tertiary fold of RrgA (upper
panel) (36). Representation of Domain III and the three defined peptides P1 (blue), P2 (green), and P3 (red) (lower panel). B, P3-Ply is themost potent of the three
fusion proteins with respect to TLR2 activation, as determined by IL-8 production by HEK-TLR2 cells. C, sequence alignment of the P3 region of RrgA from T4*
and RrgA clade II (designated RrgA-II). D, Western blotting analysis of the T4* and T4(rrgA II) strains probing for the RrgA and RrgB protein. The amount and
laddering of the pili in both strains appear similar. E, stimulation of HEK-TLR2 cells with killed pneumococcal preparation of T4* and the clade II-expressing T4
(T4(rrgA II)) reveal similar abilities to elicit TLR2-dependent responses; a killed T4ABC strain was used as a comparator. F, T4P3mutant lacking the P3 region
of the RrgA protein demonstrates no change in pilus synthesis or quantity on cell wall extract, as determined by Western blotting analysis. Additionally, the
pattern of pilus expression is similar between the wild type T4* strain and this T4P3mutant by flow cytometry using an RrgA antibody. G, P3 is necessary for
pilus-dependent TLR2 responses following stimulation with killed bacterial cells. The T4P3mutant was compared with a T4* or T4(Pilus)-killed strain with
respect to TLR2 activation in HEK-TLR2 cells. The pilus-dependent enhancement of TLR2 responses is abrogated in the T4P3mutant, which is indistinguish-
able from the T4(Pilus) strain in terms of TLR2 activity, implying that the P3 region is necessary for this response to whole bacteria. H, T4P3 mutant is not
altered in binding capacity. A binding assay on A549 cells was performed. The T4P3 and the T4* strains both bind to these cells similarly. Error bars indicate
standard deviations.
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cal type 1 pilus is a determinant of the TLR2-dependent
response to whole bacteria and is, in itself, a TLR2 agonist.
Published data by our group and others had previously iden-
tified pneumolysin and lipoteichoic acid as TLR4 and TLR2
agonists, respectively (32, 33, 48). Here, we used pneumolysin,
which does not activate TLR2, as a tool for oligomerization. It
had also been noted that, in general, the inflammatory response
to S. pneumoniae is less pronounced than to that of another
Gram-positive bacterium, Streptococcus agalactiae (49), but
these studies were based on pneumococcal strain D39, which is
nonpiliated (19). The pilus has been shown to play an important
role in the virulence and inflammatory response to pneumo-
coccus (19); here, we show that this property is mediated, at
least in part, by TLR2. Our data using whole bacteria as well as
purified pilus components further implicate a specific protein,
RrgA, as themajor determinant of TLR2 activity. RrgAhas been
described as an adhesin and binds to fibronectin, collagen 1,
and laminin (17, 50). Pilus- or RrgA-negative mutants of pneu-
mococci have been shown to be relatively less virulent than
their wild type isogenic controls. In the absence of the pilus, the
TNF- response is significantly reduced (19). RrgA-mutant
pneumococci are defective in binding to epithelial cells and
colonizing the upper respiratory tract of mice (17). Here, the
molecular basis for these properties is examined, with the dem-
onstration that the RrgA protein significantly induces a TLR2-
dependent inflammatory response in vitro. We examined this
interaction in more detail, with the demonstration that P3 of
domain III is both necessary and sufficient for pilus-dependent
TLR2 activation, as well as the virulence (as measured by den-
sity of bacteremia) and induction of TNF- responses in an
invasive diseasemodel inmice.We showed that this decrease in
virulence is not due to a reduction of binding of the mutated
RrgA protein, thus implying that the regions of the protein that
contributes to inflammation are distinct from those mediating
the adhesive properties of RrgA.
It is worth noting that the impact of the pilus on in vitro
inflammatory responses could be demonstrated not only using
HEK-TLR2 cells but also murine macrophages, which have a
fuller complement of innate immune responses. Additionally,
the role of the P3 domain could also be demonstrated in vivo in
our intraperitoneal challenge model. This result is somewhat
surprising, given the redundancy of the inflammatory response
to whole bacteria, which contain stimuli for a number of recep-
tors. Our experiments thus clearly point to the importance of
the pilus (and in particular, the 49-amino acid region of domain
III of RrgA) as a determinant of virulence and inflammatory
responses in the context of whole bacteria.
Another unexpected finding of our work is that RrgA protein
presented either as part of an oligomer or as an aggregate is far
more potent as an activator of TLR2 than themonomeric form.
The results of our evaluation of DomIII are consistent with this
observation, as DomIII alone (which forms small aggregates) or
FIGURE 5. Density of bacteremia and the TLR2-dependent pro-inflammatory response in an in vivomouse model are dependent on the P3 domain.
Intraperitoneal infectionswere performed onmicewith either live T4* or T4P3 bacterial strains inwild type (A–C) or TLR2/ (D–F) C57BL/6mice. Blood from
each mouse was recovered at 6 h post-infection for quantification of bacteremia and TNF- response. The bars in the figure represents the median and
interquartile rangeof bacteremia (A andD) and TNF- concentration in serum relative to thedensity of bacteremia in cfu (B and E) at 6 hpost-infection.p values
for comparisons of density of bacteremia and TNF- were calculated by Mann-Whitney U analysis; statistical correlation between these two variables was
examined using nonparametric methods (Spearman method) (C and F).
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DomIII-PdT did not activate HEK-TLR2 cells whereas the
DomIII-Ply fusion protein was a potent TLR2 agonist. In this
respect, our findings are reminiscent of the discovery that Dec-
tin-1, a human innate immune receptor, can similarly discrim-
inate between large aggregates of-glucans and smaller soluble
forms (51). Such a discrimination by size or degree of aggrega-
tion may be important to allow the host immune response to
react differentially to pathogens versus secreted or released
antigens derived from pathogens. Furthermore, these results
also suggest the possibility that by oligomerizing small peptides
(such as P3), defined nonlipidated molecules with potent TLR2
activity may be created with a possible role as adjuvants for
vaccines.
Many puzzling questions regarding the type 1 pneumococcal
pilus remain. In particular, if the pilus increases adherence to
host cells, why would this adhesin be present in only a minority
of strains, andwhywould its expression, as we have shown (25),
be restricted to a subpopulation of cells that contain the path-
ogenicity islet?Data presented here suggest at least one possible
explanation, which deserves further study. Although the type 1
pilus may indeed increase the adherence of pneumococcal cells
in the respiratory tract, recognition of this structure by a com-
ponent of the innate immune system may limit the advantage
that increased adherence to epithelial cells may otherwise pro-
vide. The recognition of the pilus by TLR2 may thus counter-
balance the potential benefit of the pilus to the pathogen.
In conclusion, we showhere that the RrgAprotein of the type
1 pneumococcal pilus contributes to the recognition of the
pilus by host TLR2. Peptide 3 of DomIII in particular is both
necessary and sufficient for this TLR2-mediated inflammatory
response, independently of any effect on cell adhesion. Studies
are ongoing to examine the molecular basis for the interaction
between RrgA and TLR2, the mechanism of P3 recognition by
TLR2, and the possible implications with respect to the role of
the pilus in pneumococcal fitness and virulence.
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